“Mitigation Mode: The Science of Staying Healthy While on Steroids”

7evenvox22

7evenvox22

Iron
Joined
May 29, 2025
Posts
64
Reputation
69

1) Direct free-radical scavenger (“chemical antioxidant”)​

What it does. Melatonin is amphiphilic and diffuses across membranes (cytosol, nucleus, mitochondria). It directly reacts with multiple ROS/RNS—e.g., •OH, ONOO⁻, ROO•, ¹O₂—neutralizing them before they hit lipids (like cardiolipin), proteins, or DNA. Crucially, its metabolites keep scavenging: cyclic-3-hydroxymelatonin (3-OHM) → AFMK → AMK. This “antioxidant cascade” means one melatonin molecule can eliminate multiple radicals (often cited as “up to ~10” across the cascade), extending protection beyond the parent compound. AMK, in particular, is a very reactive scavenger.

2) Indirect antioxidant (enzyme up-regulation / pro-oxidant down-shift)​

What it does. Melatonin upregulates endogenous defenses—classically via Nrf2–ARE signaling—raising transcription and activity of SOD, catalase, glutathione peroxidase, glutathione reductase, and rate-limiting glutathione enzymes (e.g., GCL). In parallel it can down-regulate pro-oxidant enzymes (e.g., iNOS/NOX/COX-2), cutting ROS/RNS production at the source. These effects are reported in cells, animal models, and some human biomarker studies; they’re partly receptor-mediated (MT1/MT2) and partly receptor-independent.

3) Epigenetic modulator​

What it does. Beyond acute redox chemistry, melatonin modulates epigenetic machinery:
  • Sirtuins (SIRT1/SIRT3): melatonin often upregulates SIRT1, a NAD⁺-dependent histone deacetylase that de-acetylates histones and key transcriptional regulators (e.g., PGC-1α), linking redox state to mitochondrial biogenesis and clock-gene output.
  • DNA methylation / demethylation: reviews summarize melatonin’s ability to influence DNMTs and TET enzymes, shifting promoter methylation patterns (reported across cancer, metabolic and neuro models).
  • Histone marks & non-coding RNAs: changes in acetylation/methylation states and miRNA profiles have been described in vitro/in vivo, including on circadian gene promoters (e.g., BMAL1/PER), tying melatonin’s clock role to chromatin. (Human evidence is emerging; much is preclinical.)

4) Mitochondrial protector​

What it does (multiple layers).
  • Made in (and enriched in) mitochondria. There’s accumulating evidence that mitochondria synthesize melatonin (AANAT/ASMT found in mitochondria), and that melatonin accumulates there—ideal placement since mitochondria generate much of a cell’s ROS.Taylor & Francis Online+1
  • Preserves the respiratory chain & lipids. Melatonin protects cardiolipin (an inner-membrane phospholipid needed for Complexes III/IV “supercomplexes”) from peroxidation, maintaining electron transport efficiency.
  • Keeps the mPTP closed. It desensitizes the mitochondrial permeability transition pore, limiting cytochrome-c release and apoptosis during oxidative or ischemia-reperfusion stress; recent work suggests interactions with F₁F₀-ATPase elements that contribute to mPTP gating.
  • Orchestrates quality control. Melatonin supports mitochondrial biogenesis (PGC-1α/NRF1/TFAM), favors fusion over fission, and promotes mitophagy to clear damaged organelles—often via SIRT1/SIRT3-PGC-1α-AMPK axes.
Why it matters. By acting inside the organelle that makes most ROS, melatonin helps maintain ΔΨm, ATP output, and lowers oxidant leakage—benefits that outlast the brief plasma half-life.

Practical implications (brief)​

  • Pharmacokinetics. Oral melatonin has low, variable bioavailability with a short half-life (~30–60 min); controlled-/sustained-release formulations extend coverage. (This is why circadian/sleep dosing looks different from high-dose antioxidant protocols in ICU research.)
  • Doses seen in studies. Antioxidant/mitochondrial biomarker effects appear from physiologic–low pharmacologic doses in health studies, while much higher doses (e.g., 50–100 mg) are being tested as adjuncts in critical illness (not routine use). Always medical-supervised at those levels.
  • Safety snapshot. Generally well-tolerated; main issues are next-day sleepiness, rare vivid dreams, and potential interactions with sedatives/anticoagulants. Keep dosing aligned with your circadian goals to avoid phase shifts.

Introduction To Hair Loss Mitigation​

Anabolic steroids can dramatically accelerate hair loss in genetically predisposed individuals due to their androgenic effects. However, with the right preventative measures, you can significantly reduce or even halt steroid-induced hair thinning.


1. Why Steroids Cause Hair Loss​

The primary culprit is dihydrotestosterone (DHT), a potent androgen derived from testosterone. Steroids like Testosterone, Trenbolone, Anadrol, and Winstrol increase DHT or bind strongly to hair follicle androgen receptors, triggering:

  • Miniaturization of hair follicles
  • Shorter growth cycles (anagen phase)
  • Progressive thinning (androgenic alopecia)
Note: Non-DHT steroids (e.g., Primobolan, Anavar) are less harsh but can still affect hair if you’re sensitive.


2. The Best Compounds to Prevent Steroid Hair Loss​

1. Dutasteride (Strongest DHT Blocker)​

  • Mechanism: Inhibits both Type I & II 5α-reductase (blocks >90% DHT vs. ~70% with Finasteride).
  • Dosage: 0.5 mg/day (oral)
  • Pros: Far stronger than Finasteride.
  • Cons: Possible systemic side effects (low libido, estrogen rise). Does not work for any other androgen apart from testosterone.

2. Finasteride (Standard DHT Defense)​

  • Mechanism: Blocks Type II 5α-reductase (lowers scalp DHT by ~60-70%).
  • Dosage: 1 mg/day (oral)
  • Best for: Low dose testosterone usage.

3. RU58841 (Topical Androgen Blocker)​

  • Mechanism: Non-steroidal anti-androgen that blocks DHT at the follicle without systemic effects.
  • Dosage: 5% solution (50mg/day) applied to scalp.
  • Pros: No sexual sides, works against all androgens
  • Cons: Limited long-term studies (but widely used in bodybuilding).

4. Ketoconazole Shampoo (2% Nizoral)​

  • Mechanism: Mild anti-androgen + reduces scalp inflammation.
  • Use: 2-3x/week (leave on for 5 mins).
  • Bonus: Helps with steroid-induced scalp acne.

5. Minoxidil (Growth Stimulant)​

  • Mechanism: Boosts blood flow to follicles, extends growth phase.
  • Use: 5% topical 2x/day (or oral Minoxidil 2.5-5 mg/day).
  • Note: Doesn’t block androgens from binding to scalp AR but helps regrow hair.

6. Pyrilutamide (Next-Gen Topical Anti-Androgen)​

  • Newer alternative to RU58841 with stronger clinical backing.
  • Dosage: 0.5% solution 2x/day (still under research).

4. Full Hair Protection Protocol​

  1. Oral: Dutasteride 0.5 mg/day (if not using DHT-derived steroids).
  2. Topical: RU58841 5% (50mg/day) + Minoxidil 5% 2x/day.
  3. Shampoo: Ketoconazole 2% 3x/week.
  4. Support: Biotin, Microneedling (1.5mm weekly).
For mild cycles (Primo, Anavar):

  • Finasteride 1 mg/day (if prone to hair loss) + Minoxidil.

5. Can You Recover Lost Hair?​

  • If follicles are alive: Yes (with DHT blockers + topical anti-androgens + growth stimulants).
  • If follicles are dead: Only a hair transplant can restore hair.
  • Key: Start prevention early—once thinning is visible, it’s harder to reverse.

6. Side Effects & Considerations​

  • Dutasteride/Finasteride: Possible libido drop (adjust dose if needed).
  • RU58841: No systemic sides reported, but long-term safety unclear.
  • Minoxidil: Shedding phase (normal, temporary).

Oxidative Stress - Pure Evil​

Oxidative stress is a state where the body’s antioxidant defenses are overwhelmed by free radicals—unstable molecules that damage cells, proteins, and DNA. It negatively impacts everything within your life.
Looks: it damages collagen and elastin and causes accelerated skin aging.
Athleticism: it damages tendons and ligaments, leading to an arthritic phenotype
Health: it can lead to auto-immune issues, cause oxidation of LDL particles,
Brain: in the short term, it causes a depressive and anxiogenic phenotype. In the long term, it causes neurodegeneration and can lead to dementia.

Antioxidant Protocol:​

To counteract oxidative stress, a robust intake of antioxidants is essential. These compounds neutralize free radicals before they cause damage. Here are some of the most effective:
  • Vitamin C - 1 gram per day: A potent water-soluble antioxidant that regenerates other antioxidants and is crucial for collagen synthesis. It protects skin, blood vessels, and brain tissue from oxidative harm.
  • Vitamin E - 400iu per day (with some dietary fat): A fat-soluble antioxidant that protects cell membranes from lipid peroxidation. It works synergistically with Vitamin C and supports neurological health. 30x stronger than Vitamin C.
  • Injectable Glutathione - 500mg 1x per week: Known as the "master antioxidant," glutathione is produced in the body and is crucial for detoxification. Levels decrease with age and chronic stress, but can be supported through diet (e.g., sulfur-rich foods) or supplementation.
  • Astaxanthin - 50mg per day: The strongest anti-oxidant (6000 times stronger than Vitamin C), and particularly selective to the skin and eyes. Very good for mitigating UV-induced oxidative stress, and likely the most potent and reducing overall skin aging.
  • Melatonin - 300mg before bed every night: The most powerful anti-oxidant for the brain. This has already had its own entire segment but it’s worth putting here again.

Introduction to Mitochondria​

Mitochondria fuel cellular energy and regulate redox balance, apoptosis, and aging. Dysfunction drives metabolic disease, neurodegeneration, and cardiovascular decline. We will summarize key interventions, including peptides (MOTS-c, SS-31, SLU-pp-332), small molecules (SR9009, methylene blue), and nutraceuticals (CoQ10, NAD+ boosters), with recommendations for a layered optimization strategy.


1. Core Targets in Mitochondrial Optimization​

  • Redox control: Scavenge ROS directly, stabilize cardiolipin, support ETC electron flow.
  • Biogenesis & mitophagy: Activate AMPK–SIRT–PGC-1α and Rev-Erb pathways; clear damaged organelles.
  • Structural protection: Preserve membrane integrity, supercomplex stability, and ATP generation.

2. Peptide and Small-Molecule Interventions​

MOTS-c​

  • Action: Mitochondria-encoded peptide; activates AMPK, improves insulin sensitivity, enhances fatty acid oxidation.
  • Use: Metabolic flexibility, age-related resistance to exercise.

SLU-pp-332​

  • Action: Potent PGC-1α/ERR agonist; boosts mitochondrial biogenesis and oxidative metabolism.
  • Use: Endurance enhancement, countering age-related mitochondrial decline.

SR9009 (Rev-Erb agonist)​

  • Action: Modulates circadian metabolism, promotes biogenesis, increases fatty acid oxidation.
  • Use: Circadian alignment, obesity-related dysfunction.

Methylene Blue​

  • Action: Redox shuttle; bypasses Complex I/III block, reduces ROS leakage.
  • Use: Neuroprotection, cognitive support, ischemia models.

SS-31 (Elamipretide)​

  • Action: Binds cardiolipin, stabilizes ETC supercomplexes, reduces cytochrome-c release and ROS.
  • Use: Mitochondrial myopathy, ischemic heart disease, muscle aging.

3. Nutraceutical Supports​

Coenzyme Q10 (Ubiquinone/Ubiquinol)​

  • Action: Native ETC electron carrier and lipid antioxidant.
  • Use: Heart failure, statin-associated myopathy, energy support.

NAD+ Boosters​

  • Agents: Nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), or indirect activators (exercise, caloric restriction mimetics).
  • Action: Replenish NAD+, activate sirtuins (SIRT1/3), enhance DNA repair and mitochondrial biogenesis.
  • Use: Aging, metabolic dysfunction, neurodegeneration models.

Alpha-Lipoic Acid (ALA)​

  • Action: Cofactor in mitochondrial enzymes, antioxidant, improves GLUT4-mediated glucose uptake.
  • Use: Insulin resistance, diabetic neuropathy, oxidative stress.

Carnitine (L-carnitine, acetyl-L-carnitine)​

  • Action: Shuttles fatty acids into mitochondria, supports acetyl-CoA flux.
  • Use: Fatigue, fatty acid oxidation defects, aging cognition.

Urolithin A​

  • Action: Induces mitophagy, enhances mitochondrial turnover.
  • Use: Age-related muscle decline; in early human trials.

4. Integrated Strategy​

  • Baseline: Exercise (HIIT + resistance), circadian alignment, micronutrients (Mg, B-vitamins).
  • Peptides: MOTS-c for metabolic signaling; SS-31 for structural protection.
  • Biogenesis inducers: SLU-pp-332 or SR9009.
  • ETC stabilizers: Methylene blue + CoQ10.
  • NAD+ support: NR/NMN/Niacin
  • Quality control: Urolithin A + ALA/carnitine stack.
Synergy principle: Combine a signaling activator (AMPK/PGC-1α), a structural stabilizer (SS-31, CoQ10), and a redox buffer (methylene blue/ALA).

- Introduction​

Steroids and Cardiovascular Stress​

Anabolic-androgenic steroids (AAS) increase cardiovascular risk through:

  • Elevated blood pressure (via sodium retention, endothelial dysfunction, increased sympathetic drive).
  • Left ventricular hypertrophy (LVH): AAS promote cardiac muscle thickening through both hemodynamic stress and direct androgen receptor signaling in the myocardium.
  • Endothelial injury and RAAS activation → stiffening of vessels, worsening hypertension.

Angiotensin Receptor Blockers​

  • ARBs (Angiotensin II Receptor Blockers) directly target the renin–angiotensin–aldosterone system (RAAS).
  • They block AT1 receptors, reducing vasoconstriction, sodium retention, and maladaptive cardiac remodeling.
  • Compared to beta blockers, ARBs are particularly effective at regressing LVH and improving vascular health.

- Mechanism of Action​

RAAS Blockade​

  • Angiotensin II normally binds AT1 receptors, causing vasoconstriction, aldosterone release, and fibrosis.
  • ARBs block AT1 → ↓ vasoconstriction, ↓ aldosterone, ↓ sodium/water retention.

Impact on Blood Pressure​

  • Vasodilation + lower blood volume → reduced systolic and diastolic pressure.

Impact on LVH​

  • Angiotensin II is a growth factor for cardiomyocytes → hypertrophy.
  • Blocking AT1 reduces myocardial hypertrophy and fibrosis.
  • Over time, ARBs can regress existing LVH, improving diastolic relaxation.

- ARB Options and Distinctions​

Telmisartan​

  • Unique: Partial PPAR-γ agonist → improves insulin sensitivity, lipid profile.
  • Strong data for LVH regression and vascular protection.
  • Ideal for AAS users with metabolic stress.

Losartan​

  • Well studied for LVH regression in hypertension and athletes.
  • Also reduces uric acid (mild uricosuric effect).
  • Shorter half-life → often dosed twice daily.

Valsartan​

  • Potent BP-lowering effect.
  • Good data in heart failure and LVH reduction.

Candesartan / Olmesartan​

  • Highly potent ARBs with strong BP control.
  • Used when monotherapy needs stronger suppression.

- Practical Use in Steroid Users (Educational)​

Goals​

  • Control blood pressure (<130/80 mmHg if possible).
  • Promote regression or stabilization of LVH.
  • Improve vascular function and reduce long-term cardiovascular risk.

Example Dosing Ranges (educational, not prescriptive)​

  • Telmisartan: 20–80 mg once daily.
  • Losartan: 50–100 mg/day (split doses possible).
  • Valsartan: 80–320 mg/day.
    (Start low and titrate; monitor kidney function and potassium.)

Integration with Other Agents​

  • Beta blockers → HR control, anti-arrhythmic effect.
  • MR antagonists (Eplerenone, Spironolactone) → anti-fibrotic, reduce remodeling.
  • Diuretics → address water retention from AAS and RAAS activation.
  • Lifestyle: Sodium restriction, aerobic training, echo/ECG monitoring.

- Evidence for LVH Regression​

  • Hypertension trials: ARBs consistently reduce LV mass more effectively than beta blockers.
  • Athlete’s heart studies: Losartan shown to reduce LV wall thickness in endurance athletes with pathological remodeling.
  • Heart failure data: Valsartan and candesartan reduce hypertrophy and fibrosis in patients with diastolic dysfunction.
  • Mechanistic edge: By blocking angiotensin II signaling directly, ARBs treat both hemodynamic and molecular drivers of LVH.

- Risks and Considerations​

  • Hyperkalemia: Especially if combined with potassium-sparing diuretics.
  • Renal function: Monitor creatinine and eGFR.
  • Hypotension: Over-aggressive dosing may cause fatigue or dizziness.
  • Combination caution: Avoid dual RAAS blockade (ACEi + ARB) - no added benefit, more risk.

- Summary​

ARBs are the frontline choice for steroid users with hypertension and LVH risk. By blocking AT1 receptors, they lower blood pressure, reduce aldosterone-driven water retention, and directly regress LVH. Among them, Telmisartan is often favored for its metabolic benefits, while Losartan has strong data in athletes. ARBs work best in combination with beta blockers (HR control) and MR antagonists (anti-fibrotic effects), plus lifestyle changes. For steroid users, they address the core driver of LVH: angiotensin II–mediated remodeling.

- The Role of Beta Blockers​

  • Beta-adrenergic receptors mediate sympathetic effects of adrenaline/noradrenaline.
  • Beta blockers antagonize these receptors, reducing heart rate, contractility, and blood pressure.
  • By decreasing cardiac workload, they help prevent or reduce LVH progression in high-risk populations, including AAS users.

- Mechanism of Action​

Sympathetic Nervous System Modulation​

  • Blocks β1 receptors in the heart → slows heart rate (negative chronotropy) and reduces contractility (negative inotropy).
  • Decreases myocardial oxygen demand.

Blood Pressure Reduction​

  • ↓ Cardiac output + ↓ renin release (β1 blockade in kidneys).
  • Reduced vascular resistance over time (indirect).

LVH Regression​

  • Chronic sympathetic drive contributes to hypertrophy.
  • Lower HR and BP → reduced wall stress → potential regression or stabilization of LVH.

- Types of Beta Blockers​

Cardioselective (β1-specific)​

  • Examples: Nebivolol, Metoprolol, Bisoprolol.
  • Preferred for AAS users: target heart and kidney with fewer bronchial side effects.
  • Nebivolol adds NO-mediated vasodilation, improving endothelial function.

Non-selective​

  • Examples: Propranolol, Nadolol.
  • Also block β2 receptors → more side effects (bronchospasm, fatigue).
  • Propranolol sometimes useful for performance anxiety (lowers adrenergic symptoms).

Mixed α/β blockers​

  • Example: Carvedilol, Labetalol.
  • Add vasodilation by blocking α1 receptors → strong BP reduction, good for LVH.
  • Carvedilol has antioxidant and anti-fibrotic properties, useful in cardiac remodeling.

- Practical Use in Steroid Users (Educational)​

Goals​

  • Control resting heart rate (target ~60–70 bpm).
  • Lower blood pressure (<130/80 mmHg ideally).
  • Reduce long-term risk of LVH and heart failure.

Dosing Principles​

  • Start low and titrate slowly to avoid bradycardia or hypotension.
  • Example educational ranges:
    • Nebivolol: 2.5–10 mg daily.
    • Metoprolol: 25–100 mg twice daily.
    • Carvedilol: 6.25–25 mg twice daily.
(These are standard therapeutic ranges, not personalized prescriptions.)

Integration with Other Cardioprotective Agents​

  • ARBs (e.g., Telmisartan, Losartan): Directly reduce LVH via RAAS blockade.
  • Mineralocorticoid antagonists (Eplerenone): Combat fibrosis.
  • Diuretics (HCTZ, amiloride): Manage fluid retention from steroids.
  • Lifestyle: Sodium restriction, aerobic conditioning, regular echocardiography.

- Evidence for LVH Regression​

  • Hypertension studies: Beta blockers reduce LV mass, though less robustly than ARBs/ACE inhibitors.
  • Carvedilol and Nebivolol: Show strongest evidence for LVH regression due to additional vasodilatory/anti-fibrotic effects.
  • In steroid users, who face both hemodynamic stress (high BP/HR) and direct androgen effects on myocardium, beta blockers mitigate at least the hemodynamic load.

- Summary​

Beta blockers are a cornerstone option for steroid users managing cardiovascular strain. By lowering heart rate and blood pressure, they reduce myocardial workload and help protect against or even regress LVH. Cardioselective (nebivolol, metoprolol) or mixed (carvedilol) agents are most practical. Best results come from combining beta blockers with ARBs, MR antagonists, and lifestyle modifications. They are not a cure for steroid-induced cardiac remodeling, but they reduce the hemodynamic burden that accelerates it.

- Introduction​

Steroid-Induced Dyslipidemia​

  • Anabolic-androgenic steroids (AAS) often cause:
    • HDL-C (sometimes to single digits).
    • LDL-C (especially small, dense LDL — most atherogenic).
    • ↑ Triglycerides (depending on diet and compound).
  • This worsens atherosclerosis risk, especially when combined with steroid-driven hypertension and LVH.

Why Lipids Matter in AAS Use​

  • Dyslipidemia is one of the strongest predictors of early cardiovascular disease in AAS users.
  • Optimizing lipids is therefore a cornerstone of harm reduction, alongside blood pressure and cardiac remodeling control.

- Mechanisms to Improve Lipids​

  1. Reduce LDL production (statins, berberine, retatrutide).
  2. Increase LDL clearance (PCSK9 inhibitors, statins, ezetimibe).
  3. Reduce triglycerides & improve insulin sensitivity (retatrutide, berberine, SR9009).
  4. Raise HDL (limited options — exercise, niacin [limited use], possibly SR9009 indirectly).
  5. Anti-atherosclerotic pleiotropy (statins, SR9009, lifestyle).

- Core Agents​

Statins (e.g., Rosuvastatin, Atorvastatin)​

  • Mechanism: HMG-CoA reductase inhibitors → reduce cholesterol synthesis.
  • Effects: ↓ LDL-C 30–60%, ↓ triglycerides modestly, slight ↑ HDL.
  • Extra benefits: Anti-inflammatory, plaque stabilization.
  • Role in AAS users: First-line if LDL-C is significantly elevated.
  • Notes: Monitor liver enzymes, muscle symptoms. Supplement CoQ10 if needed.

Ezetimibe​

  • Mechanism: Blocks intestinal cholesterol absorption (NPC1L1 transporter).
  • Effects: ↓ LDL-C ~15–25%.
  • Use: Often combined with statins if target LDL not reached.
  • Low side effect profile.

PCSK9 Inhibitors (Alirocumab, Evolocumab, Inclisiran)​

  • Mechanism: Block PCSK9 → more LDL receptors recycled → ↑ LDL clearance.
  • Effects: ↓ LDL-C up to 60%.
  • Use: Add-on for severe dyslipidemia not controlled by statins/ezetimibe.
  • Consideration: Very expensive and hard to source.

Berberine​

  • Mechanism: AMPK activation → improves insulin sensitivity, reduces hepatic gluconeogenesis, increases LDL receptor expression.
  • Effects: ↓ LDL-C, ↓ triglycerides, improves HDL modestly.
  • Additional benefits: Glycemic control — especially useful for AAS users with insulin resistance.

Retatrutide (Triple Agonist: GLP-1, GIP, Glucagon)​

  • Mechanism: Enhances satiety, energy expenditure, lipid metabolism.
  • Effects: Strong ↓ in triglycerides, modest ↓ LDL-C, ↑ insulin sensitivity.
  • Role: Very promising for obese or insulin-resistant steroid users.
  • Limitations: Experimental/early stage, GI side effects.

SR9009 (Rev-Erb Agonist; experimental)​

  • Mechanism: Regulates circadian + metabolic genes, increases fat oxidation.
  • Effects (animal studies): ↓ triglycerides, ↓ LDL, improved HDL/LDL ratio.
  • Limitations: Not yet human-approved, low oral bioavailability.

- Other Relevant Interventions​

  • Omega-3 fatty acids (EPA/DHA): ↓ triglycerides, anti-inflammatory, cardioprotective.
  • Niacin (high dose): Raises HDL, lowers LDL and TG — but flushing and liver toxicity limit use.
  • Fibrates (Fenofibrate): Strong triglyceride lowering, modest HDL ↑; useful if TG > 400.
  • Lifestyle: Aerobic training, low saturated fat diet, high fiber, avoidance of alcohol and refined carbs.

- Practical Use in Steroid Users (Educational)​

Stratified Approach​

  1. Mild dyslipidemia (LDL 100–130, HDL 30–40):
    • Lifestyle + berberine + omega-3s.
    • Consider retatrutide if insulin resistance present.
  2. Moderate (LDL 130–160, HDL <30):
    • Statin + ezetimibe.
    • Berberine as add-on.
  3. Severe (LDL >160, HDL <20, TG >250):
    • High-intensity statin + ezetimibe.
    • Add PCSK9 inhibitor if needed.
    • Omega-3/fibrate if triglycerides are very high.

Hypothetical Example Stack (Educational)​

  • Rosuvastatin 10–20 mg nightly.
  • Ezetimibe 10 mg daily if LDL goal not reached.
  • PCSK9 inhibitor if severe dyslipidemia persists.
  • Berberine 500–1500 mg/day for additional lipid + glucose benefits.
  • Omega-3s 2–4 g/day EPA/DHA for triglyceride control.
  • Retatrutide (future potential) in obese/insulin-resistant individuals.
  • SR9009 (experimental) could be layered for metabolic boost.

- Evidence for Cardiovascular Risk Reduction​

  • Statins: Proven to reduce CV events by 25–30% in general population.
  • Ezetimibe: Additive benefit when LDL not controlled.
  • PCSK9 inhibitors: Reduce CV events by ~15% on top of statins.
  • Berberine: Human studies show LDL ↓ ~20%, TG ↓ ~15%.
  • Retatrutide/GLP-1 agonists: Clinical trials show strong cardiometabolic protection.
  • SR9009: Only preclinical so far — promising but unproven.

- Risks and Considerations​

  • Statins: Muscle pain, rare rhabdomyolysis, ↑ liver enzymes.

- Comparison Table​

CompoundLDL ↓TG ↓HDL ↑NotesStatins★★★★★★★First-line, proven CV benefitEzetimibe★★——Add-on to statinsPCSK9i★★★★——For severe/resistant casesBerberine★★★★★Also improves insulin sensitivityRetatrutide★★★★★—Strong for TG + metabolic healthSR9009★★★★★Experimental, circadian/metabolic effectsOmega-3s—★★★—Triglyceride loweringNiacin★★★★★★Limited by side effectsFibrates★★★★★Strong TG lowering


- Summary​

AAS users often experience dyslipidemia (↓ HDL, ↑ LDL, ↑ TG), accelerating atherosclerosis risk. Managing lipids is as essential as controlling blood pressure or LVH in AAS users. A comprehensive stack can significantly reduce cardiovascular risk. A layered approach is best:

  • Statins are first-line for LDL reduction and proven CV protection.
  • Ezetimibe and PCSK9 inhibitors add further LDL clearance if needed.
  • Berberine and retatrutide improve insulin sensitivity and triglycerides.
  • Omega-3s/fibrates help with high TG.
  • SR9009 is a great option.

Introduction to Circadian Rhythm​

The circadian rhythm is a fundamental 24-hour oscillatory system that coordinates physiology, behavior, and metabolism with environmental light–dark cycles. Central regulation by the suprachiasmatic nucleus (SCN) integrates light cues, while peripheral clocks synchronize through hormonal and molecular signaling. Disruption of this rhythm contributes to metabolic disease, neurodegeneration, and reduced performance. This paper reviews the neural basis of circadian rhythm, molecular regulators such as Rev-Erb nuclear receptors, pharmacological/behavioral modulators including melatonin, and highlights the benefits of circadian optimization for metabolic and cellular health.

The Suprachiasmatic Nucleus and Light Cues​

The SCN, located in the hypothalamus, is the central pacemaker of circadian rhythms. Retinal ganglion cells expressing melanopsin detect blue light (~480 nm) and project via the retinohypothalamic tract to the SCN. This input resets molecular clock gene expression, aligning internal rhythms with the external day-night cycle. Exposure to artificial blue light at night delays melatonin secretion and disrupts normal sleep–wake timing, while morning light anchors circadian phase to solar time.

Rev-Erb Nuclear Receptors and Synthetic Modulators​

Rev-Erbα and Rev-Erbβ are nuclear receptors acting as transcriptional repressors within the circadian network. They couple circadian timing to metabolic regulation by suppressing lipogenesis, gluconeogenesis, and inflammatory gene programs.
  • SR9009 and related synthetic Rev-Erb agonists pharmacologically enhance Rev-Erb activity. In animal models, SR9009 increases mitochondrial biogenesis, boosts energy expenditure, and improves circadian alignment. While promising, SR9009 remains preclinical, with uncertain translational safety.

Melatonin​

The pineal gland secretes melatonin in darkness, under SCN control. Melatonin signals night-time to the body, influencing sleep onset, core temperature, and antioxidant defenses. Supplementation is widely used for circadian misalignment (jet lag, shift work), though efficacy depends on timing: evening doses advance circadian phase, while morning doses delay it. Beyond sleep, melatonin acts as both a direct free radical scavenger and an indirect antioxidant, conferring protective effects in aging and neurodegeneration.

Additional Modulators of Circadian Function​

  • Feeding–Fasting Cycles: Peripheral clocks in liver and muscle are entrained by nutrient signals. Time-restricted feeding improves metabolic health even without caloric restriction.
  • Exercise: Acts as a time cue, shifting circadian phase depending on timing.
  • Temperature Rhythms: Daily oscillations in body temperature reinforce circadian signals.
  • NAD+ boosters: Compounds such as NMN/NR enhance sirtuin activity, linking energy metabolism and circadian transcription.

Benefits of Optimal Circadian Rhythm​

Metabolic Health​

  • Lipid metabolism: Circadian alignment suppresses hepatic lipogenesis, improves lipid clearance, and lowers plasma triglycerides.
  • Insulin sensitivity: Circadian-optimized states enhance glucose uptake and reduce insulin resistance; late-night eating or disrupted rhythms impair glycemic control.

Mitochondrial Function​

  • Mitochondrial oxidative phosphorylation and biogenesis are rhythmic; alignment supports higher ATP output during active phases.
  • Rev-Erb and sirtuin signaling link circadian cycles to mitophagy, preserving mitochondrial quality.

Hormonal & Inflammatory Balance​

  • Optimized rhythms coordinate cortisol, growth hormone, and melatonin secretion, reducing chronic stress signaling.
  • Circadian balance suppresses pro-inflammatory cytokines (e.g., IL-6, TNF-α), lowering cardiometabolic disease risk.

Cognitive and Performance Outcomes​

  • Aligned circadian cycles improve reaction time, memory consolidation, and mood regulation.
  • Physical performance peaks align with circadian-driven rhythms in core body temperature and muscle function.

Hypothetical Protocol For Optimal Circadian Rhythm​

  • Flash a 10,000 lux light in your eyes immediately upon waking for 10 minutes
  • Administer 15mg of SR9009 immediately upon waking (it has no oral bioavailability, must be used transdermally or injected)
  • Get a few hours of sunlight throughout the day (if you’re nocturnal, replace this with the 10,000 lux light)
  • Use low blue light setting on screens 3 hours before bed time (or wear blue light blocking glasses)
  • Take melatonin before bed (high doses are not required for optimal circadian rhythm, though I do recommend them for other reasons)
 
  • +1
Reactions: EtherealAdonis, gigacumster3000 and theübermenschboy

1) Direct free-radical scavenger (“chemical antioxidant”)​

What it does. Melatonin is amphiphilic and diffuses across membranes (cytosol, nucleus, mitochondria). It directly reacts with multiple ROS/RNS—e.g., •OH, ONOO⁻, ROO•, ¹O₂—neutralizing them before they hit lipids (like cardiolipin), proteins, or DNA. Crucially, its metabolites keep scavenging: cyclic-3-hydroxymelatonin (3-OHM) → AFMK → AMK. This “antioxidant cascade” means one melatonin molecule can eliminate multiple radicals (often cited as “up to ~10” across the cascade), extending protection beyond the parent compound. AMK, in particular, is a very reactive scavenger.

2) Indirect antioxidant (enzyme up-regulation / pro-oxidant down-shift)​

What it does. Melatonin upregulates endogenous defenses—classically via Nrf2–ARE signaling—raising transcription and activity of SOD, catalase, glutathione peroxidase, glutathione reductase, and rate-limiting glutathione enzymes (e.g., GCL). In parallel it can down-regulate pro-oxidant enzymes (e.g., iNOS/NOX/COX-2), cutting ROS/RNS production at the source. These effects are reported in cells, animal models, and some human biomarker studies; they’re partly receptor-mediated (MT1/MT2) and partly receptor-independent.

3) Epigenetic modulator​

What it does. Beyond acute redox chemistry, melatonin modulates epigenetic machinery:
  • Sirtuins (SIRT1/SIRT3): melatonin often upregulates SIRT1, a NAD⁺-dependent histone deacetylase that de-acetylates histones and key transcriptional regulators (e.g., PGC-1α), linking redox state to mitochondrial biogenesis and clock-gene output.
  • DNA methylation / demethylation: reviews summarize melatonin’s ability to influence DNMTs and TET enzymes, shifting promoter methylation patterns (reported across cancer, metabolic and neuro models).
  • Histone marks & non-coding RNAs: changes in acetylation/methylation states and miRNA profiles have been described in vitro/in vivo, including on circadian gene promoters (e.g., BMAL1/PER), tying melatonin’s clock role to chromatin. (Human evidence is emerging; much is preclinical.)

4) Mitochondrial protector​

What it does (multiple layers).
  • Made in (and enriched in) mitochondria. There’s accumulating evidence that mitochondria synthesize melatonin (AANAT/ASMT found in mitochondria), and that melatonin accumulates there—ideal placement since mitochondria generate much of a cell’s ROS.Taylor & Francis Online+1
  • Preserves the respiratory chain & lipids. Melatonin protects cardiolipin (an inner-membrane phospholipid needed for Complexes III/IV “supercomplexes”) from peroxidation, maintaining electron transport efficiency.
  • Keeps the mPTP closed. It desensitizes the mitochondrial permeability transition pore, limiting cytochrome-c release and apoptosis during oxidative or ischemia-reperfusion stress; recent work suggests interactions with F₁F₀-ATPase elements that contribute to mPTP gating.
  • Orchestrates quality control. Melatonin supports mitochondrial biogenesis (PGC-1α/NRF1/TFAM), favors fusion over fission, and promotes mitophagy to clear damaged organelles—often via SIRT1/SIRT3-PGC-1α-AMPK axes.
Why it matters. By acting inside the organelle that makes most ROS, melatonin helps maintain ΔΨm, ATP output, and lowers oxidant leakage—benefits that outlast the brief plasma half-life.

Practical implications (brief)​

  • Pharmacokinetics. Oral melatonin has low, variable bioavailability with a short half-life (~30–60 min); controlled-/sustained-release formulations extend coverage. (This is why circadian/sleep dosing looks different from high-dose antioxidant protocols in ICU research.)
  • Doses seen in studies. Antioxidant/mitochondrial biomarker effects appear from physiologic–low pharmacologic doses in health studies, while much higher doses (e.g., 50–100 mg) are being tested as adjuncts in critical illness (not routine use). Always medical-supervised at those levels.
  • Safety snapshot. Generally well-tolerated; main issues are next-day sleepiness, rare vivid dreams, and potential interactions with sedatives/anticoagulants. Keep dosing aligned with your circadian goals to avoid phase shifts.

Introduction To Hair Loss Mitigation​

Anabolic steroids can dramatically accelerate hair loss in genetically predisposed individuals due to their androgenic effects. However, with the right preventative measures, you can significantly reduce or even halt steroid-induced hair thinning.


1. Why Steroids Cause Hair Loss​

The primary culprit is dihydrotestosterone (DHT), a potent androgen derived from testosterone. Steroids like Testosterone, Trenbolone, Anadrol, and Winstrol increase DHT or bind strongly to hair follicle androgen receptors, triggering:

  • Miniaturization of hair follicles
  • Shorter growth cycles (anagen phase)
  • Progressive thinning (androgenic alopecia)
Note: Non-DHT steroids (e.g., Primobolan, Anavar) are less harsh but can still affect hair if you’re sensitive.


2. The Best Compounds to Prevent Steroid Hair Loss​

1. Dutasteride (Strongest DHT Blocker)​

  • Mechanism: Inhibits both Type I & II 5α-reductase (blocks >90% DHT vs. ~70% with Finasteride).
  • Dosage: 0.5 mg/day (oral)
  • Pros: Far stronger than Finasteride.
  • Cons: Possible systemic side effects (low libido, estrogen rise). Does not work for any other androgen apart from testosterone.

2. Finasteride (Standard DHT Defense)​

  • Mechanism: Blocks Type II 5α-reductase (lowers scalp DHT by ~60-70%).
  • Dosage: 1 mg/day (oral)
  • Best for: Low dose testosterone usage.

3. RU58841 (Topical Androgen Blocker)​

  • Mechanism: Non-steroidal anti-androgen that blocks DHT at the follicle without systemic effects.
  • Dosage: 5% solution (50mg/day) applied to scalp.
  • Pros: No sexual sides, works against all androgens
  • Cons: Limited long-term studies (but widely used in bodybuilding).

4. Ketoconazole Shampoo (2% Nizoral)​

  • Mechanism: Mild anti-androgen + reduces scalp inflammation.
  • Use: 2-3x/week (leave on for 5 mins).
  • Bonus: Helps with steroid-induced scalp acne.

5. Minoxidil (Growth Stimulant)​

  • Mechanism: Boosts blood flow to follicles, extends growth phase.
  • Use: 5% topical 2x/day (or oral Minoxidil 2.5-5 mg/day).
  • Note: Doesn’t block androgens from binding to scalp AR but helps regrow hair.

6. Pyrilutamide (Next-Gen Topical Anti-Androgen)​

  • Newer alternative to RU58841 with stronger clinical backing.
  • Dosage: 0.5% solution 2x/day (still under research).

4. Full Hair Protection Protocol​

  1. Oral: Dutasteride 0.5 mg/day (if not using DHT-derived steroids).
  2. Topical: RU58841 5% (50mg/day) + Minoxidil 5% 2x/day.
  3. Shampoo: Ketoconazole 2% 3x/week.
  4. Support: Biotin, Microneedling (1.5mm weekly).
For mild cycles (Primo, Anavar):

  • Finasteride 1 mg/day (if prone to hair loss) + Minoxidil.

5. Can You Recover Lost Hair?​

  • If follicles are alive: Yes (with DHT blockers + topical anti-androgens + growth stimulants).
  • If follicles are dead: Only a hair transplant can restore hair.
  • Key: Start prevention early—once thinning is visible, it’s harder to reverse.

6. Side Effects & Considerations​

  • Dutasteride/Finasteride: Possible libido drop (adjust dose if needed).
  • RU58841: No systemic sides reported, but long-term safety unclear.
  • Minoxidil: Shedding phase (normal, temporary).

Oxidative Stress - Pure Evil​

Oxidative stress is a state where the body’s antioxidant defenses are overwhelmed by free radicals—unstable molecules that damage cells, proteins, and DNA. It negatively impacts everything within your life.
Looks: it damages collagen and elastin and causes accelerated skin aging.
Athleticism: it damages tendons and ligaments, leading to an arthritic phenotype
Health: it can lead to auto-immune issues, cause oxidation of LDL particles,
Brain: in the short term, it causes a depressive and anxiogenic phenotype. In the long term, it causes neurodegeneration and can lead to dementia.

Antioxidant Protocol:​

To counteract oxidative stress, a robust intake of antioxidants is essential. These compounds neutralize free radicals before they cause damage. Here are some of the most effective:
  • Vitamin C - 1 gram per day: A potent water-soluble antioxidant that regenerates other antioxidants and is crucial for collagen synthesis. It protects skin, blood vessels, and brain tissue from oxidative harm.
  • Vitamin E - 400iu per day (with some dietary fat): A fat-soluble antioxidant that protects cell membranes from lipid peroxidation. It works synergistically with Vitamin C and supports neurological health. 30x stronger than Vitamin C.
  • Injectable Glutathione - 500mg 1x per week: Known as the "master antioxidant," glutathione is produced in the body and is crucial for detoxification. Levels decrease with age and chronic stress, but can be supported through diet (e.g., sulfur-rich foods) or supplementation.
  • Astaxanthin - 50mg per day: The strongest anti-oxidant (6000 times stronger than Vitamin C), and particularly selective to the skin and eyes. Very good for mitigating UV-induced oxidative stress, and likely the most potent and reducing overall skin aging.
  • Melatonin - 300mg before bed every night: The most powerful anti-oxidant for the brain. This has already had its own entire segment but it’s worth putting here again.

Introduction to Mitochondria​

Mitochondria fuel cellular energy and regulate redox balance, apoptosis, and aging. Dysfunction drives metabolic disease, neurodegeneration, and cardiovascular decline. We will summarize key interventions, including peptides (MOTS-c, SS-31, SLU-pp-332), small molecules (SR9009, methylene blue), and nutraceuticals (CoQ10, NAD+ boosters), with recommendations for a layered optimization strategy.


1. Core Targets in Mitochondrial Optimization​

  • Redox control: Scavenge ROS directly, stabilize cardiolipin, support ETC electron flow.
  • Biogenesis & mitophagy: Activate AMPK–SIRT–PGC-1α and Rev-Erb pathways; clear damaged organelles.
  • Structural protection: Preserve membrane integrity, supercomplex stability, and ATP generation.

2. Peptide and Small-Molecule Interventions​

MOTS-c​

  • Action: Mitochondria-encoded peptide; activates AMPK, improves insulin sensitivity, enhances fatty acid oxidation.
  • Use: Metabolic flexibility, age-related resistance to exercise.

SLU-pp-332​

  • Action: Potent PGC-1α/ERR agonist; boosts mitochondrial biogenesis and oxidative metabolism.
  • Use: Endurance enhancement, countering age-related mitochondrial decline.

SR9009 (Rev-Erb agonist)​

  • Action: Modulates circadian metabolism, promotes biogenesis, increases fatty acid oxidation.
  • Use: Circadian alignment, obesity-related dysfunction.

Methylene Blue​

  • Action: Redox shuttle; bypasses Complex I/III block, reduces ROS leakage.
  • Use: Neuroprotection, cognitive support, ischemia models.

SS-31 (Elamipretide)​

  • Action: Binds cardiolipin, stabilizes ETC supercomplexes, reduces cytochrome-c release and ROS.
  • Use: Mitochondrial myopathy, ischemic heart disease, muscle aging.

3. Nutraceutical Supports​

Coenzyme Q10 (Ubiquinone/Ubiquinol)​

  • Action: Native ETC electron carrier and lipid antioxidant.
  • Use: Heart failure, statin-associated myopathy, energy support.

NAD+ Boosters​

  • Agents: Nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), or indirect activators (exercise, caloric restriction mimetics).
  • Action: Replenish NAD+, activate sirtuins (SIRT1/3), enhance DNA repair and mitochondrial biogenesis.
  • Use: Aging, metabolic dysfunction, neurodegeneration models.

Alpha-Lipoic Acid (ALA)​

  • Action: Cofactor in mitochondrial enzymes, antioxidant, improves GLUT4-mediated glucose uptake.
  • Use: Insulin resistance, diabetic neuropathy, oxidative stress.

Carnitine (L-carnitine, acetyl-L-carnitine)​

  • Action: Shuttles fatty acids into mitochondria, supports acetyl-CoA flux.
  • Use: Fatigue, fatty acid oxidation defects, aging cognition.

Urolithin A​

  • Action: Induces mitophagy, enhances mitochondrial turnover.
  • Use: Age-related muscle decline; in early human trials.

4. Integrated Strategy​

  • Baseline: Exercise (HIIT + resistance), circadian alignment, micronutrients (Mg, B-vitamins).
  • Peptides: MOTS-c for metabolic signaling; SS-31 for structural protection.
  • Biogenesis inducers: SLU-pp-332 or SR9009.
  • ETC stabilizers: Methylene blue + CoQ10.
  • NAD+ support: NR/NMN/Niacin
  • Quality control: Urolithin A + ALA/carnitine stack.
Synergy principle: Combine a signaling activator (AMPK/PGC-1α), a structural stabilizer (SS-31, CoQ10), and a redox buffer (methylene blue/ALA).

- Introduction​

Steroids and Cardiovascular Stress​

Anabolic-androgenic steroids (AAS) increase cardiovascular risk through:

  • Elevated blood pressure (via sodium retention, endothelial dysfunction, increased sympathetic drive).
  • Left ventricular hypertrophy (LVH): AAS promote cardiac muscle thickening through both hemodynamic stress and direct androgen receptor signaling in the myocardium.
  • Endothelial injury and RAAS activation → stiffening of vessels, worsening hypertension.

Angiotensin Receptor Blockers​

  • ARBs (Angiotensin II Receptor Blockers) directly target the renin–angiotensin–aldosterone system (RAAS).
  • They block AT1 receptors, reducing vasoconstriction, sodium retention, and maladaptive cardiac remodeling.
  • Compared to beta blockers, ARBs are particularly effective at regressing LVH and improving vascular health.

- Mechanism of Action​

RAAS Blockade​

  • Angiotensin II normally binds AT1 receptors, causing vasoconstriction, aldosterone release, and fibrosis.
  • ARBs block AT1 → ↓ vasoconstriction, ↓ aldosterone, ↓ sodium/water retention.

Impact on Blood Pressure​

  • Vasodilation + lower blood volume → reduced systolic and diastolic pressure.

Impact on LVH​

  • Angiotensin II is a growth factor for cardiomyocytes → hypertrophy.
  • Blocking AT1 reduces myocardial hypertrophy and fibrosis.
  • Over time, ARBs can regress existing LVH, improving diastolic relaxation.

- ARB Options and Distinctions​

Telmisartan​

  • Unique: Partial PPAR-γ agonist → improves insulin sensitivity, lipid profile.
  • Strong data for LVH regression and vascular protection.
  • Ideal for AAS users with metabolic stress.

Losartan​

  • Well studied for LVH regression in hypertension and athletes.
  • Also reduces uric acid (mild uricosuric effect).
  • Shorter half-life → often dosed twice daily.

Valsartan​

  • Potent BP-lowering effect.
  • Good data in heart failure and LVH reduction.

Candesartan / Olmesartan​

  • Highly potent ARBs with strong BP control.
  • Used when monotherapy needs stronger suppression.

- Practical Use in Steroid Users (Educational)​

Goals​

  • Control blood pressure (<130/80 mmHg if possible).
  • Promote regression or stabilization of LVH.
  • Improve vascular function and reduce long-term cardiovascular risk.

Example Dosing Ranges (educational, not prescriptive)​

  • Telmisartan: 20–80 mg once daily.
  • Losartan: 50–100 mg/day (split doses possible).
  • Valsartan: 80–320 mg/day.
    (Start low and titrate; monitor kidney function and potassium.)

Integration with Other Agents​

  • Beta blockers → HR control, anti-arrhythmic effect.
  • MR antagonists (Eplerenone, Spironolactone) → anti-fibrotic, reduce remodeling.
  • Diuretics → address water retention from AAS and RAAS activation.
  • Lifestyle: Sodium restriction, aerobic training, echo/ECG monitoring.

- Evidence for LVH Regression​

  • Hypertension trials: ARBs consistently reduce LV mass more effectively than beta blockers.
  • Athlete’s heart studies: Losartan shown to reduce LV wall thickness in endurance athletes with pathological remodeling.
  • Heart failure data: Valsartan and candesartan reduce hypertrophy and fibrosis in patients with diastolic dysfunction.
  • Mechanistic edge: By blocking angiotensin II signaling directly, ARBs treat both hemodynamic and molecular drivers of LVH.

- Risks and Considerations​

  • Hyperkalemia: Especially if combined with potassium-sparing diuretics.
  • Renal function: Monitor creatinine and eGFR.
  • Hypotension: Over-aggressive dosing may cause fatigue or dizziness.
  • Combination caution: Avoid dual RAAS blockade (ACEi + ARB) - no added benefit, more risk.

- Summary​

ARBs are the frontline choice for steroid users with hypertension and LVH risk. By blocking AT1 receptors, they lower blood pressure, reduce aldosterone-driven water retention, and directly regress LVH. Among them, Telmisartan is often favored for its metabolic benefits, while Losartan has strong data in athletes. ARBs work best in combination with beta blockers (HR control) and MR antagonists (anti-fibrotic effects), plus lifestyle changes. For steroid users, they address the core driver of LVH: angiotensin II–mediated remodeling.

- The Role of Beta Blockers​

  • Beta-adrenergic receptors mediate sympathetic effects of adrenaline/noradrenaline.
  • Beta blockers antagonize these receptors, reducing heart rate, contractility, and blood pressure.
  • By decreasing cardiac workload, they help prevent or reduce LVH progression in high-risk populations, including AAS users.

- Mechanism of Action​

Sympathetic Nervous System Modulation​

  • Blocks β1 receptors in the heart → slows heart rate (negative chronotropy) and reduces contractility (negative inotropy).
  • Decreases myocardial oxygen demand.

Blood Pressure Reduction​

  • ↓ Cardiac output + ↓ renin release (β1 blockade in kidneys).
  • Reduced vascular resistance over time (indirect).

LVH Regression​

  • Chronic sympathetic drive contributes to hypertrophy.
  • Lower HR and BP → reduced wall stress → potential regression or stabilization of LVH.

- Types of Beta Blockers​

Cardioselective (β1-specific)​

  • Examples: Nebivolol, Metoprolol, Bisoprolol.
  • Preferred for AAS users: target heart and kidney with fewer bronchial side effects.
  • Nebivolol adds NO-mediated vasodilation, improving endothelial function.

Non-selective​

  • Examples: Propranolol, Nadolol.
  • Also block β2 receptors → more side effects (bronchospasm, fatigue).
  • Propranolol sometimes useful for performance anxiety (lowers adrenergic symptoms).

Mixed α/β blockers​

  • Example: Carvedilol, Labetalol.
  • Add vasodilation by blocking α1 receptors → strong BP reduction, good for LVH.
  • Carvedilol has antioxidant and anti-fibrotic properties, useful in cardiac remodeling.

- Practical Use in Steroid Users (Educational)​

Goals​

  • Control resting heart rate (target ~60–70 bpm).
  • Lower blood pressure (<130/80 mmHg ideally).
  • Reduce long-term risk of LVH and heart failure.

Dosing Principles​

  • Start low and titrate slowly to avoid bradycardia or hypotension.
  • Example educational ranges:
    • Nebivolol: 2.5–10 mg daily.
    • Metoprolol: 25–100 mg twice daily.
    • Carvedilol: 6.25–25 mg twice daily.
(These are standard therapeutic ranges, not personalized prescriptions.)

Integration with Other Cardioprotective Agents​

  • ARBs (e.g., Telmisartan, Losartan): Directly reduce LVH via RAAS blockade.
  • Mineralocorticoid antagonists (Eplerenone): Combat fibrosis.
  • Diuretics (HCTZ, amiloride): Manage fluid retention from steroids.
  • Lifestyle: Sodium restriction, aerobic conditioning, regular echocardiography.

- Evidence for LVH Regression​

  • Hypertension studies: Beta blockers reduce LV mass, though less robustly than ARBs/ACE inhibitors.
  • Carvedilol and Nebivolol: Show strongest evidence for LVH regression due to additional vasodilatory/anti-fibrotic effects.
  • In steroid users, who face both hemodynamic stress (high BP/HR) and direct androgen effects on myocardium, beta blockers mitigate at least the hemodynamic load.

- Summary​

Beta blockers are a cornerstone option for steroid users managing cardiovascular strain. By lowering heart rate and blood pressure, they reduce myocardial workload and help protect against or even regress LVH. Cardioselective (nebivolol, metoprolol) or mixed (carvedilol) agents are most practical. Best results come from combining beta blockers with ARBs, MR antagonists, and lifestyle modifications. They are not a cure for steroid-induced cardiac remodeling, but they reduce the hemodynamic burden that accelerates it.

- Introduction​

Steroid-Induced Dyslipidemia​

  • Anabolic-androgenic steroids (AAS)often cause:
    • HDL-C (sometimes to single digits).
    • LDL-C (especially small, dense LDL — most atherogenic).
    • ↑ Triglycerides (depending on diet and compound).
  • This worsens atherosclerosis risk, especially when combined with steroid-driven hypertension and LVH.

Why Lipids Matter in AAS Use​

  • Dyslipidemia is one of the strongest predictors of early cardiovascular disease in AAS users.
  • Optimizing lipids is therefore a cornerstone of harm reduction, alongside blood pressure and cardiac remodeling control.

- Mechanisms to Improve Lipids​

  1. Reduce LDL production (statins, berberine, retatrutide).
  2. Increase LDL clearance (PCSK9 inhibitors, statins, ezetimibe).
  3. Reduce triglycerides & improve insulin sensitivity (retatrutide, berberine, SR9009).
  4. Raise HDL (limited options — exercise, niacin [limited use], possibly SR9009 indirectly).
  5. Anti-atherosclerotic pleiotropy (statins, SR9009, lifestyle).

- Core Agents​

Statins (e.g., Rosuvastatin, Atorvastatin)​

  • Mechanism: HMG-CoA reductase inhibitors → reduce cholesterol synthesis.
  • Effects: ↓ LDL-C 30–60%, ↓ triglycerides modestly, slight ↑ HDL.
  • Extra benefits: Anti-inflammatory, plaque stabilization.
  • Role in AAS users: First-line if LDL-C is significantly elevated.
  • Notes: Monitor liver enzymes, muscle symptoms. Supplement CoQ10 if needed.

Ezetimibe​

  • Mechanism: Blocks intestinal cholesterol absorption (NPC1L1 transporter).
  • Effects: ↓ LDL-C ~15–25%.
  • Use: Often combined with statins if target LDL not reached.
  • Low side effect profile.

PCSK9 Inhibitors (Alirocumab, Evolocumab, Inclisiran)​

  • Mechanism: Block PCSK9 → more LDL receptors recycled → ↑ LDL clearance.
  • Effects: ↓ LDL-C up to 60%.
  • Use: Add-on for severe dyslipidemia not controlled by statins/ezetimibe.
  • Consideration: Very expensive and hard to source.

Berberine​

  • Mechanism: AMPK activation → improves insulin sensitivity, reduces hepatic gluconeogenesis, increases LDL receptor expression.
  • Effects: ↓ LDL-C, ↓ triglycerides, improves HDL modestly.
  • Additional benefits: Glycemic control — especially useful for AAS users with insulin resistance.

Retatrutide (Triple Agonist: GLP-1, GIP, Glucagon)​

  • Mechanism: Enhances satiety, energy expenditure, lipid metabolism.
  • Effects: Strong ↓ in triglycerides, modest ↓ LDL-C, ↑ insulin sensitivity.
  • Role: Very promising for obese or insulin-resistant steroid users.
  • Limitations: Experimental/early stage, GI side effects.

SR9009 (Rev-Erb Agonist; experimental)​

  • Mechanism: Regulates circadian + metabolic genes, increases fat oxidation.
  • Effects (animal studies): ↓ triglycerides, ↓ LDL, improved HDL/LDL ratio.
  • Limitations: Not yet human-approved, low oral bioavailability.

- Other Relevant Interventions​

  • Omega-3 fatty acids (EPA/DHA): ↓ triglycerides, anti-inflammatory, cardioprotective.
  • Niacin (high dose): Raises HDL, lowers LDL and TG — but flushing and liver toxicity limit use.
  • Fibrates (Fenofibrate): Strong triglyceride lowering, modest HDL ↑; useful if TG > 400.
  • Lifestyle: Aerobic training, low saturated fat diet, high fiber, avoidance of alcohol and refined carbs.

- Practical Use in Steroid Users (Educational)​

Stratified Approach​

  1. Mild dyslipidemia (LDL 100–130, HDL 30–40):
    • Lifestyle + berberine + omega-3s.
    • Consider retatrutide if insulin resistance present.
  2. Moderate (LDL 130–160, HDL <30):
    • Statin + ezetimibe.
    • Berberine as add-on.
  3. Severe (LDL >160, HDL <20, TG >250):
    • High-intensity statin + ezetimibe.
    • Add PCSK9 inhibitor if needed.
    • Omega-3/fibrate if triglycerides are very high.

Hypothetical Example Stack (Educational)​

  • Rosuvastatin 10–20 mg nightly.
  • Ezetimibe 10 mg daily if LDL goal not reached.
  • PCSK9 inhibitor if severe dyslipidemia persists.
  • Berberine 500–1500 mg/day for additional lipid + glucose benefits.
  • Omega-3s 2–4 g/day EPA/DHA for triglyceride control.
  • Retatrutide (future potential) in obese/insulin-resistant individuals.
  • SR9009 (experimental) could be layered for metabolic boost.

- Evidence for Cardiovascular Risk Reduction​

  • Statins: Proven to reduce CV events by 25–30% in general population.
  • Ezetimibe: Additive benefit when LDL not controlled.
  • PCSK9 inhibitors: Reduce CV events by ~15% on top of statins.
  • Berberine: Human studies show LDL ↓ ~20%, TG ↓ ~15%.
  • Retatrutide/GLP-1 agonists: Clinical trials show strong cardiometabolic protection.
  • SR9009: Only preclinical so far — promising but unproven.

- Risks and Considerations​

  • Statins: Muscle pain, rare rhabdomyolysis, ↑ liver enzymes.

- Comparison Table​

CompoundLDL ↓TG ↓HDL ↑NotesStatins★★★★★★★First-line, proven CV benefitEzetimibe★★——Add-on to statinsPCSK9i★★★★——For severe/resistant casesBerberine★★★★★Also improves insulin sensitivityRetatrutide★★★★★—Strong for TG + metabolic healthSR9009★★★★★Experimental, circadian/metabolic effectsOmega-3s—★★★—Triglyceride loweringNiacin★★★★★★Limited by side effectsFibrates★★★★★Strong TG lowering


- Summary​

AAS users often experience dyslipidemia (↓ HDL, ↑ LDL, ↑ TG), accelerating atherosclerosis risk. Managing lipids is as essential as controlling blood pressure or LVH in AAS users. A comprehensive stack can significantly reduce cardiovascular risk. A layered approach is best:

  • Statins are first-line for LDL reduction and proven CV protection.
  • Ezetimibe and PCSK9 inhibitors add further LDL clearance if needed.
  • Berberine and retatrutide improve insulin sensitivity and triglycerides.
  • Omega-3s/fibrates help with high TG.
  • SR9009 is a great option.

Introduction to Circadian Rhythm​

The circadian rhythm is a fundamental 24-hour oscillatory system that coordinates physiology, behavior, and metabolism with environmental light–dark cycles. Central regulation by the suprachiasmatic nucleus (SCN) integrates light cues, while peripheral clocks synchronize through hormonal and molecular signaling. Disruption of this rhythm contributes to metabolic disease, neurodegeneration, and reduced performance. This paper reviews the neural basis of circadian rhythm, molecular regulators such as Rev-Erb nuclear receptors, pharmacological/behavioral modulators including melatonin, and highlights the benefits of circadian optimization for metabolic and cellular health.

The Suprachiasmatic Nucleus and Light Cues​

The SCN, located in the hypothalamus, is the central pacemaker of circadian rhythms. Retinal ganglion cells expressing melanopsin detect blue light (~480 nm) and project via the retinohypothalamic tract to the SCN. This input resets molecular clock gene expression, aligning internal rhythms with the external day-night cycle. Exposure to artificial blue light at night delays melatonin secretion and disrupts normal sleep–wake timing, while morning light anchors circadian phase to solar time.

Rev-Erb Nuclear Receptors and Synthetic Modulators​

Rev-Erbα and Rev-Erbβ are nuclear receptors acting as transcriptional repressors within the circadian network. They couple circadian timing to metabolic regulation by suppressing lipogenesis, gluconeogenesis, and inflammatory gene programs.
  • SR9009 and related synthetic Rev-Erb agonists pharmacologically enhance Rev-Erb activity. In animal models, SR9009 increases mitochondrial biogenesis, boosts energy expenditure, and improves circadian alignment. While promising, SR9009 remains preclinical, with uncertain translational safety.

Melatonin​

The pineal gland secretes melatonin in darkness, under SCN control. Melatonin signals night-time to the body, influencing sleep onset, core temperature, and antioxidant defenses. Supplementation is widely used for circadian misalignment (jet lag, shift work), though efficacy depends on timing: evening doses advance circadian phase, while morning doses delay it. Beyond sleep, melatonin acts as both a direct free radical scavenger and an indirect antioxidant, conferring protective effects in aging and neurodegeneration.

Additional Modulators of Circadian Function​

  • Feeding–Fasting Cycles: Peripheral clocks in liver and muscle are entrained by nutrient signals. Time-restricted feeding improves metabolic health even without caloric restriction.
  • Exercise: Acts as a time cue, shifting circadian phase depending on timing.
  • Temperature Rhythms: Daily oscillations in body temperature reinforce circadian signals.
  • NAD+ boosters: Compounds such as NMN/NR enhance sirtuin activity, linking energy metabolism and circadian transcription.

Benefits of Optimal Circadian Rhythm​

Metabolic Health​

  • Lipid metabolism: Circadian alignment suppresses hepatic lipogenesis, improves lipid clearance, and lowers plasma triglycerides.
  • Insulin sensitivity: Circadian-optimized states enhance glucose uptake and reduce insulin resistance; late-night eating or disrupted rhythms impair glycemic control.

Mitochondrial Function​

  • Mitochondrial oxidative phosphorylation and biogenesis are rhythmic; alignment supports higher ATP output during active phases.
  • Rev-Erb and sirtuin signaling link circadian cycles to mitophagy, preserving mitochondrial quality.

Hormonal & Inflammatory Balance​

  • Optimized rhythms coordinate cortisol, growth hormone, and melatonin secretion, reducing chronic stress signaling.
  • Circadian balance suppresses pro-inflammatory cytokines (e.g., IL-6, TNF-α), lowering cardiometabolic disease risk.

Cognitive and Performance Outcomes​

  • Aligned circadian cycles improve reaction time, memory consolidation, and mood regulation.
  • Physical performance peaks align with circadian-driven rhythms in core body temperature and muscle function.

Hypothetical Protocol For Optimal Circadian Rhythm​

  • Flash a 10,000 lux light in your eyes immediately upon waking for 10 minutes
  • Administer 15mg of SR9009 immediately upon waking (it has no oral bioavailability, must be used transdermally or injected)
  • Get a few hours of sunlight throughout the day (if you’re nocturnal, replace this with the 10,000 lux light)
  • Use low blue light setting on screens 3 hours before bed time (or wear blue light blocking glasses)
  • Take melatonin before bed (high doses are not required for optimal circadian rhythm, though I do recommend them for other reasons)
What a thread ! Nice information and decently elaborate:bigbrain: Repped
 
  • +1
Reactions: 7evenvox22
yea that's a pretty based insight bro. it's sick how something like melatonin can have such a powerful cascading effect on your body ngl. gotta give credit to the dudes who put in the research for that one. if you wanna post more about how this could help you while stacking, i'm curious to hear more!
 
  • +1
Reactions: 7evenvox22

Similar threads

5.5psl
Replies
42
Views
606
bruhtoobrutal
bruhtoobrutal
59H390
Replies
81
Views
2K
59H390
59H390
T4deoIncel0s
Replies
8
Views
496
T4deoIncel0s
T4deoIncel0s
BWC
Replies
26
Views
1K
BWC
BWC
satanism
Replies
9
Views
209
repulse
repulse

Users who are viewing this thread

  • Back
    Top